On March 08, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported the acceptance of two abstracts for presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting April 8-13, 2022 in New Orleans, Louisiana and virtual (Press release, Iovance Biotherapeutics, MAR 8, 2022, View Source [SID1234609666]). Details for the abstracts are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Preclinical activity and manufacturing feasibility of genetically modified PDCD-1 knockout (KO) tumor infiltrating lymphocyte (TIL) cell therapy
Presenting Author: Arvind Natarajan, Ph.D., Iovance Biotherapeutics, Inc.
Abstract Number: 2746
Poster Session: Tuesday, April 12, 2022, 9:00 a.m. – 12:30 p.m. ET, New Orleans Convention Center, Exhibit Halls D-H, Poster Section 30
Abstract Title: Trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in patients with metastatic non-small cell lung cancer (mNSCLC)
Presenting Author: Jason Alan Chesney, M.D., Ph.D., Director, James Graham Brown Cancer Center, University of Louisville
Abstract Number: CT130
Poster Session: Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. ET, New Orleans Convention Center, Exhibit Halls D-H, Poster Section 34
Posters will also be available starting at 1:00 p.m. ET on Friday, April 8, in the Virtual ePoster Hall at www.aacr.org.